These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29753836)

  • 61. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
    Ahsan N; Holman MJ; Yang HC
    Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Acyclovir plus CMV immunoglobulin prophylaxis and early therapy with ganciclovir are effective and safe in CMV high-risk renal transplant pediatric recipients.
    Ginevri F; Losurdo G; Fontana I; Rabagliati AM; Bonatto L; Valente R; Venzano P; Nocera A; Basile GC; Valente U; Gusmano R
    Transpl Int; 1998; 11 Suppl 1():S130-4. PubMed ID: 9664962
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients.
    Winston DJ; Wirin D; Shaked A; Busuttil RW
    Lancet; 1995 Jul; 346(8967):69-74. PubMed ID: 7603215
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Ganciclovir prophylaxis for cytomegalovirus interstitial pneumonitis after allogeneic bone marrow transplantation].
    Sakai R; Maruta A; Taguchi J; Tomita N; Fujita H; Kodama F; Ogawa K; Fujisawa S; Matsuzaki M; Motomura S; Okubo T
    Rinsho Ketsueki; 1996 Jan; 37(1):14-21. PubMed ID: 8683862
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant.
    Goodrich JM; Bowden RA; Fisher L; Keller C; Schoch G; Meyers JD
    Ann Intern Med; 1993 Feb; 118(3):173-8. PubMed ID: 8380242
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study.
    Sagedal S; Nordal KP; Hartmann A; Midtvedt K; Foss A; Asberg A; Degré M; Fauchald P; Rollag H
    Nephrol Dial Transplant; 2003 Sep; 18(9):1899-908. PubMed ID: 12937241
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
    McGavin JK; Goa KL
    Drugs; 2001; 61(8):1153-83. PubMed ID: 11465876
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation.
    Boeckh M; Zaia JA; Jung D; Skettino S; Chauncey TR; Bowden RA
    Biol Blood Marrow Transplant; 1998; 4(1):13-9. PubMed ID: 9701387
    [TBL] [Abstract][Full Text] [Related]  

  • 69. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial.
    Singh N; Yu VL; Mieles L; Wagener MM; Miner RC; Gayowski T
    Ann Intern Med; 1994 Mar; 120(5):375-81. PubMed ID: 8304654
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The incidence of cytomegalovirus infection in lung transplant recipients under universal prophylaxis with intravenous ganciclovir.
    Schröeder R; Michelon T; Wurdig J; Fagundes I; Schio S; Sanchez L; Camargo JJ; Sukkienik TC; Pasqualotto AC; Neumann J
    Braz J Infect Dis; 2007 Apr; 11(2):212-4. PubMed ID: 17625763
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recipients.
    Wreghitt TG; Abel SJ; McNeil K; Parameshwar J; Stewart S; Cary N; Sharples L; Large S; Wallwork J
    Transpl Int; 1999; 12(4):254-60. PubMed ID: 10460870
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir.
    Ippoliti C; Morgan A; Warkentin D; van Besien K; Mehra R; Khouri I; Giralt S; Gajewski J; Champlin R; Andersson B; Przepiorka D
    Bone Marrow Transplant; 1997 Sep; 20(6):491-5. PubMed ID: 9313883
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
    Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group.
    Schmidt GM; Horak DA; Niland JC; Duncan SR; Forman SJ; Zaia JA
    N Engl J Med; 1991 Apr; 324(15):1005-11. PubMed ID: 1848679
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Comparison of higher dose and lower dose ganciclovir for cytomegalovirus prophylaxis in seropositive heart transplant recipients.
    Lee SO; Rim JH; Sung H; Kim SH; Choi SH; Lee CW; Yun TJ; Lee JW; Woo JH; Kim YS; Kim JJ
    Transpl Infect Dis; 2010 Feb; 12(1):31-7. PubMed ID: 19843292
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Preemptive therapy with intravenous ganciclovir for the prevention of cytomegalovirus disease in lung transplant recipients.
    Monforte V; Román A; Gavaldà J; Bravo C; Gispert P; Pahissa A; Morell F
    Transplant Proc; 2005 Nov; 37(9):4039-42. PubMed ID: 16386621
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.
    Shiley KT; Gasink LB; Barton TD; Pfeiffenberger P; Olthoff KM; Blumberg EA
    Liver Transpl; 2009 Aug; 15(8):963-7. PubMed ID: 19642123
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience.
    Lopez Garcia-Gallo C; García Fadul C; Laporta R; Portero F; Millan I; Ussetti P
    Ann Transplant; 2015 Nov; 20():661-6. PubMed ID: 26537426
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].
    Gane E; Saliba F; Valdecasas GJ; O'Grady J; Pescovitz MD; Lyman S; Robinson CA
    Lancet; 1997 Dec; 350(9093):1729-33. PubMed ID: 9413463
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas-kidney transplant recipients.
    López-Medrano F; Rueda B; Lizasoain M; Juan RS; Folgueira D; Andrés A; Morales JM; Jiménez C; Meneu JC; Aguado JM
    Transpl Infect Dis; 2009 Oct; 11(5):400-4. PubMed ID: 19570139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.